AGES scores had similar odds of abstinence in line with the effects of active or placebo treatment received. We explored potential interaction of AGES with gender and FTND. When added as a set, neither of these interaction terms of AGES with FTND (β=0.001; se=0.02, p<0.97) or gender (b=−0.06; se=0.07; p<0.40) were statistically significant in models evaluating lapse risk. Interaction terms evaluating AGES with FTND (β =−0.02; se=0.03, p<0.50) or gender (β =0.04; se= 0.12; p<0.73) also were not significant in the PPA-EOT model.
